Overview of Cost-Effectiveness and Limitations of Next-Generation Sequencing in Colorectal Cancer
In the last decade, the introduction of next-generation sequencing (NGS) and bioinformatic tools for medical research and clinical practice has significantly impacted the management of cancer. Progressing from the detection of gene alterations and data an
- PDF / 4,615,018 Bytes
- 191 Pages / 439.42 x 683.15 pts Page_size
- 77 Downloads / 151 Views
lluminating Colorectal Cancer Genomics by Next-Generation Sequencing A Big Chapter in the Tale
Illuminating Colorectal Cancer Genomics by Next-Generation Sequencing
Khalid El Bairi Editor
Illuminating Colorectal Cancer Genomics by Next-Generation Sequencing A Big Chapter in the Tale
Editor Khalid El Bairi Cancer Biomarkers Working Group Oujda, Morocco
ISBN 978-3-030-53820-0 ISBN 978-3-030-53821-7 https://doi.org/10.1007/978-3-030-53821-7
(eBook)
# The Editor(s) (if applicable) and The Author(s), under exclusive licence to Springer Nature Switzerland AG 2020 This work is subject to copyright. All rights are solely and exclusively licensed by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This Springer imprint is published by the registered company Springer Nature Switzerland AG. The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
We wrote this book with love for oncology and cancer science. Khalid El Bairi
To my parents (Mohammed and Fatima) and my family for always supporting me To Dr. Hind Kadiri (PhD) and Pr. Maryam Fourtassi (MD, PhD) And particularly to cancer patients
Preface
Colorectal cancer is a devastating disease and is the second most common cause of cancer death annually worldwide. Although screening programs have reduced deaths from colon cancer in older age groups, worryingly and for unknown reasons, the incidence of colorectal cancer in younger populations is increasing rapidly. The management of colon cancer has changed fundamentally over the past decade, moving from generic chemotherapy regimens to a more personalized approach. Cancer genomics has been at the heart of these changes; for example, RAS testing has improved patient selection for anti-EGFR therapy, and BRAF-directed treatment has emerged as a new standard in BRAFV600E mutant colorectal cancers. It is a great pleasure to be asked to write a preface to this book. The initial chapters build on a review of
Data Loading...
